Search Results - "Sule, Neal"

CAPTAIN STUDY: ASSOCIATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS WITH LUNG FUNCTION AND PATIENT-REPORTED OUTCOMES IN A LARGE RANDOMIZED PHASE III CLINICAL TRIAL.

Authors: Sule, Neal Fowler, Andrew Kerstjens, Huib et al.

Source: CHEST. 2020 Supplement, Vol. 158, pA35-A38. 4p.

Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).

Authors: Yang, Shuying Lee, Laurie A. Sule, Neal et al.

Source: Clinical Pharmacokinetics. Jul2021, Vol. 60 Issue 7, p887-896. 10p.

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.

Authors: Dimopoulos, Meletios Athanasios Beksac, Meral Pour, Ludek et al.

Source: New England Journal of Medicine. 8/1/2024, Vol. 391 Issue 5, p408-421. 14p.

CAPTAIN STUDY: EFFECT OF BASELINE LUNG FUNCTION ON RESPONSE TO TRIPLE THERAPY IN PATIENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID/LONG-ACTING BETA2-AGONIST THERAPY.

Authors: Nathan, Robert Boulet, Louis-Philippe Kerstjens, Huib et al.

Source: CHEST. 2020 Supplement, Vol. 158, pA2621-A2625. 5p.

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.

Authors: Mateos MV Trudel S Quach H et al.

Source: Blood advances [Blood Adv] 2025 Nov 25; Vol. 9 (22), pp. 5708-5719.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.

Authors: Dimopoulos MA Beksac M Pour L et al.

Corporate Authors: Dimopoulos MA Beksac M Pour L et al.

Source: The Lancet. Haematology [Lancet Haematol] 2025 Nov; Vol. 12 (11), pp. e876-e886.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.

Authors: Hanafin P Ho YL Papathanasiou T et al.

Source: Targeted oncology [Target Oncol] 2025 Sep; Vol. 20 (5), pp. 833-845. Date of Electronic Publication: 2025 Sep 16.

Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.

Authors: Dimopoulos MA Hungria VTM Radinoff A et al.

Source: The Lancet. Haematology [Lancet Haematol] 2023 Oct; Vol. 10 (10), pp. e801-e812.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.

Authors: Lee LA Bailes Z Barnes N et al.

Source: The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Jan; Vol. 9 (1), pp. 69-84. Date of Electronic Publication: 2020 Sep 09.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE